Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05696366 · ClinicalTrials.gov registry record · Phase 1
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
A Phase 1 study of Type 1 Diabetes, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05696366 is a Phase 1 study of Type 1 Diabetes that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 24 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05696366, a Phase 1 study of Type 1 Diabetes, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single site, double-blind, placebo-controlled, crossover trial to quantify the effects of combination adjunctive therapy on glycemic control, ketogenesis during insulinopenia, insulin resistance, and diabetes burden and quality of life.
Conditions Studied
Interventions
- DRUG Sotagliflozin
- DRUG Volagidemab
Study Locations (1)
California
- UC San Diego Altman Clinical & Translational Research Institute - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05696366
The ClinicalTrials.gov registry entry for NCT05696366 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Sotagliflozin is the first listed.
NCT05696366 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05696366 about?
NCT05696366 is a clinical study titled "Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes". This is a single site, double-blind, placebo-controlled, crossover trial to quantify the effects of combination adjunctive therapy on glycemic control, ketogenesis during insulinopenia, insulin resistance, and diabetes burden and quality of life.
What is the current status of trial NCT05696366?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-09-09. Estimated completion is 2028-01.
What conditions does trial NCT05696366 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT05696366?
The interventions under investigation include: Sotagliflozin (DRUG), Volagidemab (DRUG).
Who is sponsoring clinical trial NCT05696366?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05696366 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Denosumab for Type 1 Diabetes
RECRUITING · Phase 1
-
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
RECRUITING · Phase 1
-
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
RECRUITING · Phase 1
-
A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.